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Platelet counts and mean platelet volume in association with 
serum magnesium in maintenance hemodialysis patients
Mahmoud Rafieian-Kopaie¹, Hamid Nasri²’*¹Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran²Department of Nephrology, Isfahan University of Medical Sciences, Isfahan, Iran
Introduction: Platelet dysfunction is responsible for increased bleeding tendency of chronic renal failure patients. Magnesium (Mg) retention can occur in patients on maintenance hemodialysis.
Objectives: Studies concerning the impact of magnesium disturbances on platelet counts and mean volume in hemodialysis are quiet scarce.
Patients and Methods: A total of 36 (f= 15, m= 21), HD patients were included. The mean patients’ age was 46 (±16) years. The mean length of time patients had received hemodialysis was 32 (±36) (median: 19) months.
Results: The mean platelet count was 165 (±70) (median: 163) [x103μ/L]. The mean platelet 
volume was 9 (±1) (median: 9.2) fl. The mean Mg was 9.2 ±1.4 (median: 2.4) mg/dl. In this study a 
significant inverse correlation of platelet count with mean platelet volume (r= -0.39, p= 0.017) was 
seen. A significant inverse correlation of serum Magnesium with mean platelet volume (r= -0.37, 
p= 0.025) was seen. There was not significant association of serum Mg and PLT count was found too (p> 0.05).
Conclusion: A significant inverse correlation of serum Magnesium with mean platelet volume 
needs further investigations to clarify the clinical significance of this finding.
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Implication for health policy/practice/research/medical education:Platelet dysfunction is responsible for increased bleeding tendency of chronic renal failure patients. Magnesium retention can occur 
in patients on maintenance hemodialysis. In a study on 36 chronic hemodialysis patients, we found a significant inverse correlation 
of serum magnesium with mean platelet volume. This finding needs further investigations to clarify its clinical significance.
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IntroductionEnd-stage renal disease patients mostly suffer from various hemostatic disorders (1). Bleeding tendency in uremic patients is high, due to abnormalities of primary hemostasis (1,2). This is particularly attributed to platelet dysfunction (1,2). In this regard, the most important abnormalities are related to decreased availability of platelet factor-3, defective platelet aggregation, adhesiveness, and prolongation of the bleeding time (2,3). The implicated mechanisms include: increased vessel wall prostacyclin, 
abnormal platelet arachidonic acid, increased levels of 
parathyroid hormone, platelet (PLT) inhibition by various plasma metabolites, such as urea, guanidinosuccinic acid, and phenolic acid metabolism (1-3). Regarding the PLT count, hematologic analyzers have introduced a reliable index. In association with the platelet parameter, the mean platelet volume (MPV) has been described (2-4). MPV 
is a determinant and a relatively a good marker for PLT function in that large platelets are more active than normal sized ones. Mean platelet volume, which is considered as a 
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measure of platelet size, reflects changes in either the rate of platelet production or the level of platelet stimulation (3-6). Increased mean platelet volume may indicate increased numbers of large, hyperaggregable platelets or increased platelet activation which is accepted as an independent coronary artery risk factor (3-8). In general population, MPV is usually considered as an independent risk factor for myocardial infarction (MI) and coronary heart disease in hemodialysis (HD) patients (4,5). Magnesium (Mg) is the eight most common elements in the crust of the Earth (6-8). It is an important intracellular cation which is distributed into three major compartments: mineral phase of bones (65%), intracellular space (34%) and 
extracellular fluid (1%) (6-8). In HD patients, both total and ionized magnesium  levels  are often slightly elevated above the normal range and have been shown to be dependent on residual renal function (6-10). Mg has various physiological functions in the body in health and in diseases.  Mg retention can occur in patients on maintenance HD (10-13). 
ObjectivesRegarding the present data, studies regarding the association of magnesium disturbances in maintenance HD with platelet counts and MPV are quit scarce. We therefore aimed to elucidate whether in patients with uremia on hemodialysis, the level of plasma Magnesium affects the mean platelet volume and count. 
Patients and Methods 
PatientsThe etiologies of renal failure were diabetic nephropathy, hypertension, various glomerular diseases, autosomal 
dominant poly cystic kidney disease (ADPKD) and also urinary tract infections . Due to the severity of secondary hyperparathyroidism, each patient was treated with calcium carbonate capsules, and Rena-Gel (sevelamer; 
Genzyme Europe B.V.; United Kingdom/Ireland) capsules and vitamin D3 tablets (Calcitriol; Rocaltrol) (Roche 
Hexagon; Roche Laboratories Inc, New Jersey, USA), at various doses. Due to the severity of anemia, patients were received  iron sucrose, (Venofer -International Inc. St. Gallen Switzerland) intravenously, at various doses after each dialysis session . Patients were also administered 
6 mg/day/day folic acid, 500 mg/day Acetyl-L-Carnitine 
(Jarrow Formulas, Inc™ Los Angeles, CA), 2,000 U intravenous Eprex (recombinant human erythropoietin 
[Rhuepo] [Janssen-Cilag; Cilag - AG International 6300 Zug, 
Switzerland) and one vitamin B-complex tablet/day after each dialysis session. Exclusion criteria were any active or chronic infection and use of angiotensin converting 
enzyme inhibitors, Non-steroidal anti-inflammatory drugs or the use of other drugs having adverse effects on platelet production or function. 
Laboratory methods Blood samples were collected from patients after an 
overnight fasting. Complete blood count containing mean 
platelet volume (MPV) (Ref. Range 7.5-11.5 fl) and platelet 
count were measured using a Sysmex-KX-21N cell counter (Sysmex Corporation; Mundelein, Illinois, Sysmex America, 
Inc.). Level of serum magnesium (Mg), calcium (Ca), 
phosphorus (P) and also alkaline phosphatase (ALP) were measured using standard kits. Duration and dosages of HD treatment were calculated from the patients’ records. The duration of each HD session was 4 hours. For patients predialysis creatinine, BUN and post dialysis BUN were measured. The urea reduction ratio was calculated using the formula 100 × (1-[Ct/Co]), in which Co is the predialysis blood urea nitrogen and Ct is the blood urea nitrogen 
measured five minutes after the end of dialysis.
Ethical issues(1) The research followed the tenets of the Declaration of Helsinki; (2) informed consent was obtained; (3) the research was approved by the institutional review board. 
Statistical analysis Statistical correlations were evaluated using the partial correlation test. Results are expressed as means±SD. Statistical analyses were done using SPSS 11.5 (SPSS Inc, 
Chicago, IL). P less than 0.05 was considered as statistically 
significant. 
Results The total patients were 36 (f= 15, m= 21). The mean patients’ age was 46 (±16) years. The mean length of time patients had received HD was 32 (±36) (median: 19) months. The 
mean PLT count was 165 (±70) (median: 163) [x103µ/L]. 
The mean MPV was 9 (±1) (median: 9.2) fl. The mean Mg 
was 9.2±1.4 (median: 2.4) mg/dl. Table 1, summarized 
patients’ data. In this study a significant inverse correlation of platelet count with mean platelet volume (r= -0.39, p= 
0.017) was seen. A significant inverse correlation of serum Mg with MPV (r= -0.37, p= 0.025; Figure 1) was seen. There 
was not significant association of serum Mg and PLT count was found (p> 0.05). 
Discussion 
In this study we found a significant inverse correlation of 
PLT count with mean platelet volume. A significant inverse correlation of serum Mg with MPV was also found. The greatest role in the development of haemostatic disturbances in HD patients is ascribed to the platelets (14). Other than platelet count, the mean platelet volume is used by clinician, however, its role in the diagnosis and management of patients is unclear. While factors which during HD affect 
volume PLT and count are under investigation, it is believed that platelet aggregation and activation, and coagulative activation are the most important and earliest phenomena 
that occur after contact between artificial membranes and blood (15,16). Mean platelet volume is a physiological factor of hemostatic importance (15-17). Large platelets 18 Journal of Renal Injury Prevention, Volume 1, Number 1, January 2012 http://journalrip.com          
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are more reactive and aggregate more easily (16-18). Furthermore, they contain more dense granules and release more serotonin in comparison to small platelets (16-19). There are not any nuclei in platelets and their characteristics are evaluated by their progenitor cells, the bone marrow megakaryocytes (16-20). The platelet density and volume are determined at thrombopoiesis and when in the circulation, platelets do not change in size (21-23). The mechanisms that control the platelet production are not fully understood, although it has been suggested that both platelet counts and MPV are under independent hormonal control (23,24). It should be noted that larger platelets are more reactive (23,24). The inverse association of platelet count with mean platelet volume, shown in our study, was also shown in the studies conducted by others (25,26). An inverse correlation between platelet number and platelet volume has been reported in 564 normal subjects and 297 pregnant women (26). In our previous study regarding 
association of C-reactive protein with PLT count and MPV 
in HD patients, we found a significant inverse correlation of MPV with serum CRP (27). In this study no significant 
correlation of PLT count and serum CRP was found (p>0.05) 
Table 1. Mean±SD, minimum  and  maximum  of age, duration  and 
doses  of  hemodialysis  and  also laboratory  results  of  patients
Total patients=36 Minimum Maximum Mean
Age years 16 80 46±16
DH*  months 2 156 32± 36 
Dialysis 36 1584 294± 393 
Dose sessions
URR% 39 76 59± 9
Creat mg/dl 3 18 9± 3
BUN mg/dl 30 180 82± 33
Ca mg/dl  5 10 7.6± 0.9
Alb g/dl 24 4.8 3.8± 0.5
PLT count
[x103µ/L] 264 396 165± 70
MPV (fl) 7 11 9± 1
Hgb g/dl 5 13 9± 2
HCT% 14 40 28± 6
*Duration of hemodialysis treatment
(28). In another study on the same patients, we found a 
significant positive association between PLT count and plasma HCO3- and also a significant inverse correlation of MPV with plasma HCO3- were found (28). To understand the impact of parathormone on platelet count and MPV in HD patients, we also conducted a study in which we found, 
a near significant positive correlation between the mean 
platelet volume and serum parathormone. A significant inverse correlation between platelet count and serum parathormone was also seen (29). Magnesium ion (Mg2+) is found to play an important role in cell activation (28-31). It was found that, Mg2+ deficiency is associated with platelet hyper-reactivity (28-31). Previous studies have 
shown reduced PLT release of β-thromboglobulin and thromboxane B2 with increasing magnesium concentrations 
(0.5–8.0 mmol/l) (30-33). In addition, magnesium has also been shown to reduce thrombin-stimulated Ca+2 influx in platelets (30-33). Magnesium has been shown to reduce platelet aggregation both in vitro and ex vivo (30-34). To 
the best of our knowledge, this is the first report concerning association of platelets count and mean volume with serum Mg in HD patients. Hence, further studies are needed to 
clarify the clinical significance of this finding.
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Figure 1. Significant inverse association of serum Mg with MPV.
Rafieian-Kopaie MR et al.
20 Journal of Renal Injury Prevention, Volume 1, Number 1, January 2012 http://journalrip.com        
Ethical considerations Ethical issues (including plagiarism, informed consent, misconduct, double publication and redundancy) have been completely observed by the authors.
Funding/SupportNone.
References 1. Krawczyk W, Dmoszynska A, Sokolowska B. Evaluation of platelet hemostasis in patients with chronic renal failure. Wiad Lek 1994; 47: 93-9.2. Jubelirer SJ. Hemostatic abnormalities in renal disease. 
Am J Kidney Dis 1985; 5: 219-25. 3. Bancroft AJ, Abel EW, Mclaren M, Belch JJ. Mean platelet volume is a useful parameter: a reproducible routine 
method using a modified Coulter thrombocytometer. 
Platelets 2000; 11: 379-87.          4. Ozdemir O, Soylu M, Alyan O. Association between mean platelet volume and autonomic nervous system 
functions: Increased mean platelet volume reflects sympathetic over activity. Clin Cardiol 2004; 9: 243-47.  5. Henning BF, Zidek W, Linder B, Tepel M. Mean platelet volume and coronary heart disease in hemodialysis patients. Kidney Blood Press Res 2002; 25:103-8.6. Hwang DL, Yen CF, Nadler JL. Effect of extracellular magnesium on platelet activation and intracellular calcium mobilization. Am J Hypertens 1992; 5: 700-6.7. Shechter M, Sharir M, Paul Labrador MJ, Forrester J, Silver B,  Merz NB. Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation 2000; 102: 2353-8.8. Navarro-González JF. Magnesium in dialysis patients: serum levels and clinical implications. Clin Nephrol 1998; 49: 373-8. 9. Baradaran A, Nasri H. Correlation of serum magnesium with serum parathormone levels in patients on regular hemodialysis. Saudi J Kidney Dis Transpl 2006; 17: 344-50.10. Ravn HB, Vissinger H, Kristensen SD, Wennmalm A, 
Thygesen K , Husted SE. Magnesium inhibits platelet activity: an infusion study in healthy volunteers. Thromb 
Haemost 1996; 75: 939-44.11. Nasri H, Baradaran A. Correlation of serum magnesium with dyslipidemia in maintenance hemodialysis patients. Acta Medica (Hradec Kralove) 2004; 47: 263-5.12. Wyskida K, Witkowicz J, Chudek J, Więcek A. Daily magnesium intake and hypermagnesemia in hemodialysis patients with chronic kidney disease. J 
Ren Nutr 2012; 22:19-26. 13. Navarro-González JF, Mora-Fernández C, Garcí�a-Pérez J. Clinical implications of disordered magnesium homeostasis in chronic renal failure and dialysis. Semin 
Dial 2009; 22(1): 37-44. 14. Coli L, De Sanctis LB, Feliciangeli G, Iannelli S, Scolari MP, Todeschini P, et al. Dialysis membrane biocompatibility: 
effects on cellular elements. Nephrol Dial Transplant 1995; 10: 27-32.         15. Martin JF, Trowbridge A, eds. Platelet Heterogeneity: 
Biology and Pathology. London, UK: Springer-Verlag; 1990.         16. Jakubowski JA, Thomson CB, Vaillancourt R, Valeri CR, Deykin D. Arachidonic acid metabolism by platelets of differing size. Br J Haematol 1983; 53: 503-11.         17. Martin JF, Trowbridge EA, Salmon G, Plumb J. The 
biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb 
Res 1983; 32: 443-60.         18. Haver VM, Gear ARL. Functional fractionation of platelets. J Lab Clin Med 1981; 97: 187-204.     19. Thompson CB, Eaton KA, Princiotta SM, Kushkin CA, Valeri CR. Size dependent platelet subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity and function. Br J Haematol 1982; 50: 509-19.         20. Thompson CB, Jakubowski JA, Quinn PG, Deykin D, Valeri CR. Platelet size as a determinant of platelet function . J 
Lab Clin Med 1983; 101: 205-13.         21. Thomson CB, Love DG, Quinn PG, Valeri CR. Platelet size does not correlate with platelet age. Blood 1983; 62: 487-94.22. Martin JF. The relationship between megakaryocyte ploidy and platelet volume. Blood Cells 1989; 15:108-17. 23. Martin JF, Plumb J, Kilby RS, Kishk YT. Changes in platelet volume and density in myocardial infarction. Br 
Med J 1983; 287: 456-9.         24. Sharpe PC, Desai ZR, Morris TC. Increase in mean platelet volume in patients with chronic renal failure treated with erythropoietin. J Clin Pathol 1994;47: 159-61.         25. Bancroft AJ, Abel EW, Mclaren M, Belch JJ. Mean platelet volume is a useful parameter: a reproducible routine 
method using a modified Coulter thrombocytometer. 
Platelets 2000; 11: 379-87.         26. Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol 2011; 25: 391-403. 27. Lamparelli RD, Baynes RD, Atkinson P, Bezwoda WR, Mendelow BV. Platelet parameters. Part I. Platelet counts and mean platelet volume in normal and pregnant subjects. S Afr Med J 1988; 73: 36-9.28. Nasri H, Shirani Sh, Baradaran A. Association of platelet count and mean platelet volume with serum C-reactive protein in regular hemodialysis patients. Asian J Cell 
Biol 2006; 1: 59-64.29. Baradaran A, Nasri H. Impact of parathormone hormone on platelet count and mean volume in end-stage renal failure patients on regular hemodialysis. J Med Sci 2005; 5: 266-271.         30. Nasri H, Baradaran A. Platelet count and mean volume 
Platelet counts and mean volume and magnesium
21Journal of Renal Injury Prevention, Volume 1, Number 1, January 2012http://journalrip.com                                               
(MPV) in association with plasma HCO3- in Rregular hemodialysis patients. Rev Bras Hematol Hemoter 2006; 28: 127-30. 31. Tauszig ME, Picker SM, Gathof BS. Platelet derived cytokine accumulation in platelet concentrates treated for pathogen reduction. Transfus Apher Sci 2012; 46: 33-7. 32. Nasri H. Influence of serum homocysteine on platelet count in stable hemodialysis patients. Pak J Physiol 2006; 2: 4-7.33. Angiolillo DJ, Hwang C, Datto C, Desai B, Sostek M. 
Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial. Clin Ther 2011; 33: 1883-93. 34. Takaya J, Kaneko K. Small for gestational age and magnesium in cord blood platelets: intrauterine 
magnesium deficiency may induce metabolic syndrome in later life. J Pregnancy 2011; 2011: 270474. 
